PIK3CA-related overgrowth spectrum (PROS) is a group of rare, incurable disorders caused by mutations in the PIK3CA gene that result in the malformation and overgrowth of various parts of the body. A new report to be published January 26 in the Journal of Experimental Medicine (JEM) describes the successful treatment of two young infants with PROS using the breast cancer drug alpelisib.
PROS encompasses a group of diseases that, taken together, is thought to affect around 1 in 70,000 people. Mutations in the PIK3CA gene alter the growth and proliferation of cells, causing the malformation or excessive growth of various tissues, including the brain, blood vessels, muscle, and bone, which often results in severe disability and premature death.
Though some PROS symptoms can be alleviated through surgery and other forms of palliative care, there are currently no medical treatments approved to treat the disease. However, alpelisib, a PIK3CA inhibitor recently approved to treat certain forms of breast cancer, has shown promising results in both animal models of PROS and a small number of adult and older pediatric patients. The drug is now being investigated in a series of larger clinical trials, but, until now, there have been no data on alpelisib’s efficacy in young infants with PROS.
In the new JEM study, a team of researchers led by Professor Guillaume Canaud (Necker-Enfants Malades Hospital, AP-HP; Université Paris Descartes; Inserm) identified two young patients—an 8-month-old girl and a 9-month-old boy—with a variety of severe symptoms caused by mutations in the PIK3CA gene. These symptoms included extreme blood vessel malformations and asymmetrical overgrowth of limbs and digits, as well as, in the boy’s case, an enlarged right brain hemisphere associated with epileptic spasms.
Daily oral doses of 25 mg alpelisib induced a rapid and significant clinical improvement in all of these symptoms. In the girl’s case, for example, 12 months of alpelisib treatment reduced the amount of vascular malformations and substantially decreased the size of her right leg, allowing her to stand and walk with assistance, while the boy’s epileptic spasms were greatly reduced.
The children’s overall development appeared to be significantly improved, and neither patient showed any adverse effects of alpelisib treatment. Further analyses revealed that, at a daily dose of 25 mg, the levels of alpelisib that accumulated in the children’s blood were much lower than the levels that can be safely tolerated by adults.
“Given the well-established safety profile of alpelisib at the approved 300-mg dose in adults, these low exposures support the continuous treatment of 25 mg alpelisib in these young patients with PROS,” Canaud says. “The results of alpelisib treatment in these two infants are encouraging, but they should be interpreted with caution and will have to be confirmed by future studies.”
Morin et al. 2022. J. Exp. Med. https://rupress.org/jem/article-lookup/doi/10.1084/jem.20212148?PR
# # #
About Journal of Experimental Medicine
Journal of Experimental Medicine (JEM) publishes peer-reviewed research on immunology, cancer biology, stem cell biology, microbial pathogenesis, vascular biology, and neurobiology. All editorial decisions on research manuscripts are made through collaborative consultation between professional scientific editors and the academic editorial board. Established in 1896, JEM is published by Rockefeller University Press, a department of The Rockefeller University in New York. For more information, visit jem.org.
Visit our Newsroom, and sign up for a weekly preview of articles to be published. Embargoed media alerts are for journalists only.
Follow JEM on Twitter at @JExpMed and @RockUPress.
Journal of Experimental Medicine
Method of Research
Subject of Research
Treatment of two infants with PIK3CA-related overgrowth spectrum by alpelisib
Article Publication Date
F. Dubos reported personal fees from Sanofi-Pasteur, MSD, and Takeda outside the submitted work. T.K. Han reported being an employee at Novartis. F. Branle reported "other" from Novartis.Pharma.AG during the conduct of the study; and is a full-time employee of Novartis.Pharma AG Switzerland. A patent application (“BYL719 [alpelisib] for use in the treatment of PIK3CA-related overgrowth spectrum”; #WO2017140828A1) has been filed by Institut National de la Sant e et de la Recherche M edicale, Centre National De La Recherche Scientifique, Universit e Paris Descartes, and Assistance Publique-Hˆopitaux De Paris for the use of BYL719 (alpelisib) in the treatment of PIK3CA-related overgrowth spectrum (PROS/ CLOVES syndrome). G. Canaud is the inventor. G. Canaud receives or has received consulting fees from Novartis, Vaderis, Fresenius Medical Care, Alkermes, IPSEN, and BridgeBio. No other disclosures were reported.